With the generic product portfolio of imaging agents, Sanochemia focuses on the development, manufacture and authorisation of imaging agents as well as on the cost effectiveness of these products. Imaging agents are administered during X-ray or MRI (magnetic resonance imaging) examinations and facilitate a clear and meaningful depiction of the organs. This is often required for deciding on treatment.
Sanochemia strives to expand the product portfolio of imaging agents in the coming years.

Vidon^® (PVP-hypericin)
Vidon^® is a pioneering technology for treating bladder cancer. Vidon^® is developed by Sanochemia as both a diagnostic as well as a therapeutic option for patients with non-muscle invasive bladder cancer. 
As a patented, photoactive active ingredient, Vidon^® is used in the diagnosis of urinary bladder tumours. After administration of the agent to the urinary bladder and selective enrichment in malignant tissue, suspicious tumour areas can be made visible during the cystoscopic inspection with blue light (photodynamic diagnostics, PDD). PDD with Vidon^® eases the early detection of very small and flat tumours and their fundamental removal. In clinical studies, Vidon^® shows significantly improved tumour detection compared to the gold standard as well as a distinct safety profile.
One new treatment concept for non-muscle invasive bladder cancer is photodynamic therapy (PDT) with PVP-hypericin. PDT is the combination of a physical and chemical mode of action for destroying tumours. The effect is achieved with assistance from red light. PDT with PVP-hypericin in bladder cancer is currently in the pre-clinical development stage. PDT with PVP-hypericin shall replace instillation therapy in the future.
Vidon^® was licensed to the Newfield Therapeutics Corporation for further clinical development and commercialisation in America, Canada, Australia and parts of Asia.

Anti-tumour peptides
Anti-tumour peptides that aim to treat malignant melanoma are being investigated as part of a joint research project with the University of Graz.

Tolperisone is a muscle relaxant developed to treat acute, painful muscle spasms accompanying back pain, and spasticity accompanying neurological diseases. 
Tolperisone has a dual effect with its unique mode of action: it affects both the peripheral neural system as well as the spinal cord and brain stem. This alleviates severe muscle cramps and improves patient mobility. Although tolperisone is centrally effective, it has only minor potential for sedation.

Tolperisone was licensed to Neurana Pharmaceuticals and is currently undergoing clinical development. SANOCHEMIA's partner Neurana Pharmaceuticals successfully completed the Phase 2 clinical trial in 2019 and plans to commence the Phase 3 clinical trial with tolperisone in 2020.